Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 28:28:e00548.
doi: 10.1016/j.btre.2020.e00548. eCollection 2020 Dec.

Review of clinical applications of radiation-enhancing nanoparticles

N Scher  1 , S Bonvalot  2 , C Le Tourneau  3   4   5 , E Chajon  6 , C Verry  7   8 , J Thariat  9 , V Calugaru  1
Affiliations
Review

Review of clinical applications of radiation-enhancing nanoparticles

N Scher et al. Biotechnol Rep (Amst). .

Abstract

Purpose: Clinical evidence of the radiation-enhancing effects of nanoparticles has emerged.

Materials and methods: We searched the literature in English and French on PubMed up to October 2019. The search term was "nanoparticle" AND "radiotherapy", yielding 1270 results.

Results: The two main NP used in clinical trials were hafnium oxide and gadolinium involving a total of 229 patients. Hafnium oxide NP were used in three phase 1/2 trials on sarcoma, head and neck squamous cell carcinoma or liver cancer and one phase 2/3 trial. There are six ongoing phase 1/2 clinical trials to evaluate the combination of gadolinium-based NP and RT for the treatment of brain metastases and cervical cancer.

Conclusion: So far, intratumoral hafnium oxide nanoparticles were safe and improved efficacy in locally advanced sarcoma.

Keywords: Cancer; Nanoparticles; Radiotherapy.

PubMed Disclaimer

Conflict of interest statement

NS, EC, CV: None SB: honorarium, travel grant, meeting grant, unrestricted grant for the phase 1/2 and phase 3 trials NBTXR3 in sarcoma CLT: Participation in advisory boards from Nanobiotix JT: personal fees from Nanobiotix VC: personal fees from Nanobiotix

Figures

Fig. 1
Fig. 1
Flow diagram for selection of studies.
Fig. 2
Fig. 2
List of completed and ongoing clinical trials evaluating nanoparticles activated by radiotherapy.
See this image and copyright information in PMC

References

    1. Rancoule C., Magné N., Vallard A., Guy J.-B., Rodriguez-Lafrasse C., Deutsch E. Nanoparticles in radiation oncology: from bench-side to bedside. Cancer Lett. 2016;375(June (2)):256–262. - PubMed
    1. Laurence M., Darmon A., Vivet S., Polrot M., Zhang P., Deutsch E. Abstract 2665: NBTXR3 hafnium oxide nanoparticle activated by ionizing radiation demonstrates marked radio-enhancement and antitumor effect via high energy deposit in human soft tissue sarcoma. Cancer Res. 2011;71(April (8 Supplement)):2665.
    1. Marill J., Mohamed Anesary N., Paris S. DNA damage enhancement by radiotherapy-activated hafnium oxide nanoparticles improves cGAS-STING pathway activation in human colorectal cancer cells. Radiother. Oncol. 2019;141(December):262. - PubMed
    1. Bonvalot S., Le Pechoux C., De Baere T., Buy X., Italiano A., Stockle E. Phase I study of NBTXR3 nanoparticles, in patients with advanced soft tissue sarcoma (STS) J. Clin. Oncol. 2014;32(May (15_suppl)):10563.
    1. Bonvalot S., Rutkowski P.L., Thariat J., Carrère S., Ducassou A., Sunyach M.-P. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial. Lancet Oncol. 2019;20(August (8)):1148–1159. - PubMed

LinkOut - more resources